# Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
Canonical URL: https://biopharmsignal.com/news/SRRK/scholar-rock-to-report-second-quarter-2026-financial-results-on-august-6-2026-4387875b
Ticker: SRRK
Company: Scholar Rock
Source: Scholar Rock
Published: 2026-07-16 12:00 EST
Original Source URL: https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-report-second-quarter-2026-financial-results-august
## Summary

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 16, 2026-- Scholar Rock (NASDAQ: SRRK) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management

## Article Body
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 16, 2026-- Scholar Rock (NASDAQ: SRRK) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026, before the financial markets open.

The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com .

To participate via telephone, please register in advance here . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call.

An archived replay of the webcast will be available on the Company’s website for approximately 90 days.

About Scholar Rock

Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com , including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website, X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260716882246/en/

Source: Scholar Rock
## Recent Company News
- 2026-07-17 20:15 EST — [Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SRRK/scholar-rock-reports-new-employee-inducement-grants-under-nasdaq-listing-rule-56-f0ff2185) — Source: Scholar Rock
- 2026-07-16 12:00 EST — [Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/SRRK/scholar-rock-to-report-second-quarter-2026-financial-results-on-august-6-2026-4387875b) — Source: Scholar Rock
- 2026-06-22 12:00 EST — [Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD](https://biopharmsignal.com/news/SRRK/scholar-rock-to-showcase-neuromuscular-research-portfolio-at-2026-annual-cure-sm-c0fc71a6) — Source: Scholar Rock
- 2026-06-12 20:15 EST — [Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SRRK/scholar-rock-reports-new-employee-inducement-grants-under-nasdaq-listing-rule-56-77f7a745) — Source: Scholar Rock
- 2026-05-26 13:30 EST — [Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/SRRK/scholar-rock-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Scholar Rock
## Related News
- 2026-07-22 21:05 EST — SUPN — [Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2026-financial-results-and-h-58b4f63d)
- 2026-07-22 20:15 EST — MOH — [Molina Healthcare Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/MOH/molina-healthcare-reports-second-quarter-2026-financial-results-343e2d32)
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)